NRC Health (NRC) 주식 분석

회사 개요

National Research Corporation is a specialized entity within the healthcare sector that focuses on delivering analytics and insights designed to measure and enhance patient and employee experiences across United States healthcare organizations. The company operates specifically within the health information services industry, providing market experience solutions as well as subscription-based services aimed at improving the tracking of awareness, perception, and other qualitative metrics. As of the latest reporting period, the corporation holds a market capitalization of $387.60M and generates annual revenue of $137.39M, employing a workforce of 357 individuals to support its operational capabilities. These valuation and revenue figures position the company as a mid-sized player in the broader health information services landscape, reflecting a niche focus on data-driven solutions rather than mass-market pharmaceuticals or broad healthcare equipment manufacturing.

재무 건전성

The company reported revenue of $137.39M and net income of $11.29M over the trailing twelve months, while EBITDA stood at $37.00M, highlighting a significant gap between gross earnings before interest, taxes, depreciation, and amortization and the final net profit that indicates substantial operating expenses or interest costs impacting the bottom line. Free cash flow for the period was $16.65M, which suggests the company maintains a degree of financial flexibility despite its debt obligations, allowing for potential capital expenditures or operational adjustments without immediate reliance on external financing. The gross margin stands at 61.9%, indicating a high-margin service model typical of software or analytics firms, while the operating margin of 32.2% and profit margin of 8.4% reveal that while operational efficiency is present, costs related to interest or taxes significantly erode the final profitability relative to total revenue. The balance sheet shows a total cash balance of $4.14M against total debt of $80.24M, resulting in a debt-to-equity ratio of 573.55, which characterizes the company as highly leveraged and reliant on equity financing to service its obligations. Additionally, the current ratio of 0.55 indicates that current assets are insufficient to cover current liabilities, signaling potential short-term liquidity constraints that require careful management of working capital. Return on equity is reported at 51.2% and return on assets at 13.7%, metrics that suggest management is generating substantial returns on the shareholders' capital and utilizing the company's asset base effectively, even amidst the high leverage profile.

밸류에이션 평가

The stock carries a trailing P/E ratio of 34.08 compared to a forward P/E of 14.69, a stark divergence that implies the market expects a significant contraction in earnings in the near term, causing the forward valuation to appear much more attractive despite the high historical multiple. The price-to-book ratio is 27.57, suggesting that the market values the company at a substantial premium over its book value, likely reflecting expectations of intangible asset appreciation or future growth that are not currently captured in the balance sheet book value. Alternative valuation metrics such as a price-to-sales ratio of 2.82 and an EV/EBITDA of 12.53 provide further context, with the price-to-sales multiple indicating the company commands a premium for its revenue stream relative to peers, while the EV/EBITDA suggests the earnings power is valued at a moderate multiple when debt is accounted for. The stock traded within a 52-week range between $9.76 and $22.79, meaning the current price sits significantly below the recent high, reflecting a period of consolidation or decline relative to the previous year's peak performance. With a beta of 0.41, the stock exhibits low price volatility relative to the broader market, indicating that its price movements are less sensitive to general market fluctuations and may offer a lower risk profile for those seeking stability.

Growth & Income

Revenue growth declined by 4.6% year-over-year while earnings growth contracted sharply by 74.4%, indicating that earnings are shrinking at a much faster rate than revenue, which points to deteriorating profitability margins or increased cost pressures that are disproportionately affecting the bottom line compared to top-line sales. The company currently offers a dividend yield of 3.2% with a payout ratio of 104.0%, a situation where dividends paid exceed net income, which generally signals that the payout is not sustainable given the current earnings trajectory and may be supported by cash reserves or debt financing. Given the negative earnings growth and the payout ratio exceeding 100%, the company is effectively unable to fund dividends through current operations, necessitating a reliance on retained earnings or balance sheet strength to maintain the dividend stream. Overall, the growth and income profile presents a challenging environment characterized by declining earnings, high leverage, and a dividend policy that exceeds current profitability, requiring close monitoring of operational improvements to restore financial sustainability.